Chris Williams
Fortuna: 41 729 $ al 31/07/2026
Fortuna: 41 729 $ al 31/07/2026
Chris Williams is Chief Business Development Officer & Senior VP at Autolus Therapeutics Plc since 2024.
Former roles include Non-Executive Director at Autolus Ltd. and Director at Orchard Therapeutics (Europe) Ltd. Education includes graduate studies at Imperial College London and undergraduate studies at the University of Cardiff.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AUTOLUS THERAPEUTICS PLC 0,02 % | 18/03/2026 | 28.006 ( 0,02 % ) | 41 729 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Corporate Officer/Principal | 01/02/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Director/Miembro de la Junta | - |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cardiff
University of Cardiff Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Health Technology |
Autolus Therapeutics Plc
Autolus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of gene therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.